The role of EBV in the pathogenesis of Burkitt’s Lymphoma: an Italian hospital based survey

Infectious Agents and Cancer

Pantaleo Bufo¹  Angela Santoro⁷  Eduardo Bucci²  Paolo Bucci²  Gabriella Aquino⁸  Annarosaria De Chiara⁸  Renato Franco⁸  Vittoria Donofrio³  Maria Elena Errico³  Pasquale Somma⁴  Simona Cagiano⁶  Maria Carmela Pedicillo⁶  Mirella Pace⁶  Rosanna Zamparese⁵  Giuseppe Pannone⁶ 

[1] IRCCS CROB - Basilicata Cancer Institute, Rionero in Vulture, Potenza, Italy;Department of Odontostomatological and Maxillofacial Sciences, University of Napoli ‘Federico II’, Naples, Italy;Section of Pathological Anatomy, Paediatric Oncological Hospital Pausillipon, Naples, Italy;Section of Pathological Anatomy, Ospedale dei Colli – Monaldi, Napoli, Italy;Section of Pathological Anatomy Ospedale di Ascoli, Ascoli Piceno, Italy;Department of Clinical and Experimental Medicine, Institute of Pathological Anatomy, University of Foggia, Foggia, Italy;Piazza Attilio Omodei Zorini, 48, int.6 00166, Rome, RM, Italy;Pathology Unit - Istituto Nazionale dei Tumori, Naples, Italy

关键词: In situ hybridization;    Immunohistochemistry;    Burkitt’s lymphoma;   

Others  :  1161151
DOI  :  10.1186/1750-9378-9-34

 received in 2013-06-18, accepted in 2014-09-28,  发布年份 2014

【 摘 要 】

The exact worldwide incidence of Burkitt’s lymphoma is not known. There are three distinct clinical variants of Burkitt’s lymphoma, each manifesting differences in epidemiology, clinical presentation, morphology, biology and genetic features: the endemic (African), the sporadic (non-endemic), and the immunodeficiency-associated form. In particular, we reported data regarding Burkitt’s lymphoma incidence in the world and across different European countries. Finally, we described clinic-pathological data of 48 Burkitt’s lymphomas occurred in Italy from 2003 to 2013, in 4 different hospitals, two of which located in east side, and the other ones located in the west-coast. Forty Burkitt’s lymphomas occurs in children (age range 3–12), and 8 were adulthood Burkitt’s lymphomas (age range 18–87). In the pediatric group the Male:Female ratio (M:F) was of 4:1, whereas the group of the adult patients has a M:F of 1:1.67. Immunohistochemical detection of Latent Membrane Protein 1 (LMP1) expression and Epstein-Barr virus Encoded RNA (EBER) In Situ Hybridization (ISH) procedures have been performed. Lymphocyte B monoclonal spread has been demonstrated using a Polymerase Chain Reaction (PCR) based method to amplify Fragment Restriction FR1, FR2 and FR3 immunoglobulin heavy chains DNA fragments. Only 38 cases out of 48 were analyzed for LMP-1 showing various percentage of stained cells in 47.4% of the patients.

Considering ISH for EBER detection results:

– 1 out 2 (50%) adult analyzed cases was positive, with 50% of stained tumor cells (this patient was a 22 years old female, coming from Napoli);

– 15 out 24 (62.5%) children analyzed Burkitt’s lymphomas resulted as positive for EBER;

– the overall positivity has been observed in 16/26 Burkitt’s lymphomas (61.53%).

– Finally, EBV has been detected in children and adult patients, one of them with deregulation of the oncogene c-MYC by chromosomal translocation.

【 授权许可】

   
2014 Pannone et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Durand-Panteix S, Farhat M, Youlyouz-Marfak I, Rouaud P, Ouk-Martin C, David A, Faumont N, Feuillard J, Jayat-Vignoles C: B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels. J Immunol 2012, 189:181-190.
• [2]Ocheni S, Olusina DB, Oyekunle AA, Ibegbulam O, Kröger N, Bacher U, Zander AR: EBV-Associated Malignancies. The Open Infectious Dis J 2010, 4:101-112.
• [3]Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF: Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood 1998, 91(4):1373-1381. Erratum in: Blood 1998 Apr 15;91(8):3091
• [4]Wright DH: Burkitt’s lymphoma: a review of the pathology, immunology, and possible etiologic factors. Pathol Annu 1971, 6:337-363.
• [5]de Thé G, Geser A, Day NE, Tukei PM, Williams EH, Beri DP, Smith PG, Dean AG, Bronkamm GW, Feorino P, Henle W: Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt’s lymphoma from Ugandan prospective study. Nature 1978, 274(5673):756-761.
• [6]Crawford DH: Biology and disease associations of Epstein–Barr virus. Philos Trans R Soc Lond B Biol Sci 2001, 356461-356473.
• [7]Andreone P, Gramenzi A, Lorenzini S, Biselli M, Cusaro C, Pileri S, Bernardi M: Posttransplantation lymphoproliferative disorders. Arch Intern Med 2003, 163:1997-2004.
• [8]Holman CJ, Karger AB, Mullan BD, Brundage RC, Balfour HH Jr: Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder. Clin Transplant 2012, 26:741-747.
• [9]Merlino C, Cavallo R, Bergallo M, Giacchino F, Bollero C, Negro Ponzi A, Cavallo G: Epstein-Barr viral load monitoring by quantitative PCR in renal transplant patients. New Microbiol 2003, 26:141-149.
• [10]Orii T, Ohkohchi N, Kikuchi H, Koyamada N, Chubachi S, Satomi S, Kimura H, Hoshino Y, Morita M: Usefulness of quantitative real-time polymerase chain reaction in following up patients with Epstein-Barr virus infection after liver transplantation. Clin Transplant 2000, 14(4 Pt 1):308-317.
• [11]Niedobitek G: Epstein-Barr virus infection in the pathogenesis ofnasopharyngeal carcinoma. J Clin Pathol Mol Pathol 2000, 53:248-254.
• [12]Sousa H, Pinto-Correia AL, Medeiros R, Dinis-Ribeiro M: Epstein-Barr virus is associated with gastric carcinoma: The question is what is the significance? World J Gastroenterol 2008K, 14:4347-4351.
• [13]Hecht JL, Aster JC: Molecular biology of Burkitt’s lymphoma. J Clin Oncol 2000, 18:3707-3721.
• [14]Wright DH: The epidemiology of Burkitt’s tumor. Cancer Res 1967, 27:2424-2438.
• [15]Thorley-Lawson DA: Epstein–Barr virus: exploiting the immune system. Nat Rev Immunol 2001, 1:75-82.
• [16]Henle W, Henle G: The Epstein-Barr Virus. Berlin: Springer; 1979:61-78.
• [17]Kelly G, Bell A, Rickinson A: Epstein–Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med 2002, 8:1098-1104.
• [18]Niedobitek G, Agathanggelou A, Rowe M, Jones EL, Jones DB, Turyaguma P, Oryema J, Wright DH, Young LS: Heterogeneous expression of Epstein–Barr virus latent proteins in endemic Burkitt’s lymphoma. Blood 1995, 86:659-665.
• [19]Brady G, MacArthur GJ, Farrell PJ: Epstein–Barr virus and Burkitt lymphoma. J Clin Pathol 2007, 60:1397-1402.
• [20]Bieging KT, Swanson-Mungerson M, Amick AC, Longnecker R: Epstein-Barr Virus in Burkitt’s Lymphoma: a role for Latent Membrane Protein 2A. Cell Cycle 2010, 9(5):901-908.
• [21]Magrath I: Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br J Haematol 2012, 156(6):744-756.
• [22]Burkitt DP, Nelson CL, Williams EH: Some geographical variations in disease pattern in East and Central Africa. East Afr Med J 1963, 40:1-6.
• [23]Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS: Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006, 107:265.
• [24]Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, Marcos-Gragera R, Maynadié M, Simonetti A, Lutz JM, Berrino F: Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010, 116:3724-3734.
• [25]Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW: World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008.
• [26]Boerma EG, van Imhoff GW, Appel IM, Veeger NJ, Kluin PM, Kluin-Nelemans JC: Gender and age-related differences in Burkitt lymphoma –epidemiological and clinical data from The Netherlands. Eur J Cancer 2004, 40:2781.
• [27]Magrath IT, Sariban E: Clinical features of Burkitt’s lymphoma in the USA. IARC Sci Publ 1985, 60:119-127.
• [28]Guech-Ongey M, Simard EP, Anderson WF, Engels EA, Bhatia K, Devesa SS, Mbulaiteye SM: AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood 2010, 116:5600.
• [29]Raphael M, Gentilhomme O, Tulliez M, Byron PA, Diebold J: Histopathologic features of high grade non–Hodgkin’s lymphomas in acquired immunodeficiency syndrome. The French Study group of Pathology for Human Immunodeficiency Virus-Associated Tunors. Arch Pathol Lab Med 1991, 115:15-20.
• [30]Cardy AH, Sharp L, Little J: Burkitt’s Lymphoma: A Review of the Epidemiology. Kuwait Med J 2001, 33(4):293-306.
• [31]Burkitt DP: Determining the climatic limitations of a children’s cancer common in Africa. Br Med J 1962, 2:1019-1023.
• [32]Burkitt DP: Discovering Burkitt’s lymphoma. In Epstein-Barr Virus and Human Disease. Edited by Levine PH, Ablashi DV, Nonoyana M, Pearson GR, Clifton GR. New Jersey: Humana Press Incorporated; 1989.
• [33]Khanna R, Burrows SR, Moss DJ: Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev 1995, 59:387-405.
• [34]Rickinson AB, Kieff E: Epstein-Barr virus. In Field’s Virology. Edited by Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE. Philadelphia, P.A: Lippincott-Raven; 1996:2397-2446.
• [35]Magrath IT: African Burkitt’s lymphoma: histology, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol 1991, 13:222-246.
• [36]Hummel M, Anagnostopoulos I, Korbjuhn P, Stein H: Epstein-Barr virus in B-cell non- Hodgkin’s lymphomas: unexpected infection patterns and different infection incidence in low- and high-grade types. J Pathol 1995, 175:263-271.
• [37]Shapira J, Peylan-Ramu N: Burkitt’s lymphoma. Oral Oncol 1998, 34:15-23.
• [38]Leder P, Battey J, Lenoir G, Moulding C, Murphy W, Potter H, Stewart T, Taub R: Translocations among antibody genes in human cancer. Science 1983, 222:765-771.
• [39]Klein G, Klein E: Myc/Ig juxtaposition by chromosomal translocations: some new insights, puzzles and paradoxes. Immunol Today 1985, 6:208-215.
• [40]Dalla-Favera R, Martinotti S, Gallo RC, Erickson J, Croce CM: Translocation and rearrangements of the c-myc oncogene locus in human undiff e rentiated B-cell lymphomas. Science 1983, 219:963-967.
• [41]Pelicci P, Knowles DM, Magrath I, Dalla-Favera R: Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A 1986, 83:2984.
• [42]Dalla-Favera GG: R. Molecular pathogenesis of AIDS-related lymphomas. Adv Cancer Res 1995, 67:113-153.
• [43]Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WWL, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, His ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, et al.: The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012, 44(12):1321-1325.
• [44]Diebold J: Burkitt lymphoma. In Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Edited by Jaffe E, Harris N, Stein H, Vardiman JW. Washington, DC: IARC Press; 2001:181-184.
• [45]Blum KA, Lozanski G, Byrd JC: Adult Burkitt leukemia and lymphoma. Blood 2004, 104:3009-3020.
• [46]Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, Lutz P, Coze C, Perel Y, Raphaël M, Terrier-Lacombe MJ, Société Française d’Oncologie Pédiatrique: The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001, 97:3370-3379.
• [47]Bowman WP, Shuster JJ, Cook B, Griffin T, Behm F, Pullen J, Link M, Head D, Carroll A, Berard C, Murphy S: Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small non-cleaved-cell lymphoma: a Pediatric Oncology Group study. J Clin Oncol 1996, 14:1252-1261.
• [48]Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, Neely J, Arndt C, Nieder M, Jaffe E, Wittes RA, Horak ID: Adults and children with small non-cleaved-cell lymphoma have similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996, 14:925-934.
• [49]Nakamura N, Nakamine H, Tamaru J, Nakamura S, Yoshino T, Ohshima K, Abe M: Thedistinction between Burkitt lymphoma and diffuse large B-cell lymphoma with cmyc rearrangement. Mod Pathol 2002, 15:771-776.
• [50]Haralambieva E, Boerma EJ, van Imhoff GW, Rosati S, Schuuring E, Müller-Hermelink HK, Kluin PM, Ott G: Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol 2005, 29:1086-1094.
• [51]Frost M, Newell J, Lones MA, Tripp SR, Cairo MS, Perkins SL: Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol 2004, 121:384-392.
• [52]Lenze D, Leoncini L, Hummel M, Volinia S, Liu CG, Amato T, De Falco G, Githanga J, Horn H, Nyagol J, Ott G, Palatini J, Pfreundschuh M, Rogena E, Rosenwald A, Siebert R, Croce CM, Stein H: The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia 2011, 25:1869-1876.
• [53]Gulley ML, Glaser SL, Craig FE, Borowitz M, Mann RB, Shema SJ, Ambinder RF: Guidelines for Interpreting EBER In Situ Hybridization and LMP1 Immunohistochemical Tests for Detecting Epstein-Barr Virus in Hodgkin Lymphoma. Am J Clin Pathol 2002, 117:259-267.
• [54]Khan G, Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson DA: Is EBV persistence in vivo a model for B cell homeostasis? Immunity 1996, 5:173-179.
• [55]MacMahon EME, Ambinder RF: EBER in situ hybridisation: Sensitive detection of latent Epstein-Barr virus in individual cells. Rev Med Virol 1994, 4:251-260.
• [56]Gulley ML: Molecular Diagnosis of Epstein-Barr Virus-Related Diseases. J Mol Diagn 2001, 3(1):1-9.